Bacterial Effector as Anti-Bacterial Protein
AssigneeBattelle Memorial Institute
InventorsHeather BAUMANN, Rachael HARDISON, Fadime Kara MURDOCH
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of using the Legionella pneumophilia effector protein, LegC4, either intracellularly generated or extracellularly delivered to cells, as an anti-microbial agent to treat or prevent intracellular microbial infections.
Claims20
A method of treating mammalian cells to suppress the numbers of an intracellular pathogen present in mammalian cells contacted with said intracellular pathogen, relative to non-treated mammalian cells contacted with said intracellular pathogen, said method comprising increasing the intracellular concentration of a polypeptide having at least 95% sequence identity to SEQ ID NO:
- 2 in said cells or having at least 95% sequence identity to peptide fragment of SEQ ID NO:
- 2, wherein said fragment is at least 20 amino acids in length, with the proviso that the intracellular bacterial pathogen is not Legionella pneumophilia.
A method of inhibiting the infection of a mammalian cell by an intracellular pathogen, said method comprising the step of increasing the intracellular concentration of a polypeptide having at least 95% sequence identity to SEQ ID NO:
- 2 (LegC4) in said cells or having at least 95% sequence identity to peptide fragment of SEQ ID NO:
- 2, wherein said fragment is at least 20 amino acids in length, with the proviso that the intracellular bacterial pathogen is not Legionella pneumophilia, optionally wherein the mammalian cell is a human cell.
A delivery vehicle comprising
- i) a polypeptide having at least 95% sequence identity to SEQ ID NO:
- 2, or a peptide fragment thereof having at least 95% sequence identity to a contiguous fragment of SEQ ID NO:
- 2, wherein said fragment is at least 10, 15, 20, 30, 50, 100, 300, 500 or 1,000 amino acids in length, or
- ii) a polynucleotide encoding a polypeptide having at least 95% sequence identity to SEQ ID NO:
- 2, or a peptide fragment thereof having at least 95% sequence identity to a contiguous fragment of SEQ ID NO:
- 2, wherein said fragment is at least 10, 15, 20, 30, 50, 100, 300, 500 or 1,000 amino acids in length.
Dependencies are inferred from the claim text.